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Abstract
Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are
commonly prescribed to the growing number of cancer patients (more than two million in the UK alone) often to
treat hypertension. However, increased fatal cancer in ARB users in a randomized trial and increased breast cancer
recurrence rates in ACEI users in a recent observational study have raised concerns about their safety in cancer
patients. We investigated whether ACEI or ARB use after breast, colorectal or prostate cancer diagnosis was
associated with increased risk of cancer-specific mortality.
Methods: Population-based cohorts of 9,814 breast, 4,762 colorectal and 6,339 prostate cancer patients newly
diagnosed from 1998 to 2006 were identified in the UK Clinical Practice Research Datalink and confirmed by cancer
registry linkage. Cancer-specific and all-cause mortality were identified from Office of National Statistics mortality
data in 2011 (allowing up to 13 years of follow-up). A nested case–control analysis was conducted to compare
ACEI/ARB use (from general practitioner prescription records) in cancer patients dying from cancer with up to five
controls (not dying from cancer). Conditional logistic regression estimated the risk of cancer-specific, and all-cause,
death in ACEI/ARB users compared with non-users.
Results: The main analysis included 1,435 breast, 1,511 colorectal and 1,184 prostate cancer-specific deaths
(and 7,106 breast, 7,291 colorectal and 5,849 prostate cancer controls). There was no increase in cancer-specific
mortality in patients using ARBs after diagnosis of breast (adjusted odds ratio (OR) = 1.06 95% confidence interval (CI)
0.84, 1.35), colorectal (adjusted OR = 0.82 95% CI 0.64, 1.07) or prostate cancer (adjusted OR = 0.79 95% CI 0.61, 1.03).
There was also no evidence of increases in cancer-specific mortality with ACEI use for breast (adjusted OR = 1.06 95% CI
0.89, 1.27), colorectal (adjusted OR = 0.78 95% CI 0.66, 0.92) or prostate cancer (adjusted OR = 0.78 95% CI 0.66, 0.92).
Conclusions: Overall, we found no evidence of increased risks of cancer-specific mortality in breast, colorectal or
prostate cancer patients who used ACEI or ARBs after diagnosis. These results provide some reassurance that
these medications are safe in patients diagnosed with these cancers.
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Background
Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II receptor blockers (ARBs) are commonly
prescribed to the large and growing number of individuals
with cancer (for example, currently more than two million
in the UK [1] and 13 million in the US [2]) often to treat
hypertension which affects around 40% of cancer patients
[3]. However, the possible effect of ACEIs and ARBs on
cancer is subject to much debate. Concerns were first raised
in 2003 when the Candesartan in Heart Failure Assessment
of Reduction in Mortality and Morbidity (CHARM) trial
[4] unexpectedly reported a significant 40% increase in fatal
cancer in patients randomized to candesartan (an ARB)
compared with placebo (relative risk (RR) = 1.42 95% CI
1.02, 1.98; P = 0.04). In part conducted because of this find-
ing, a 2010 meta-analysis of randomized trials observed in-
creased cancer risk with ARBs [5]. Preclinical studies also
suggested a biological rationale for an increase in cancer
risk in ARB users [6,7]. A later meta-analysis observed no
association for ARBs but observed a small increased risk
of cancer in combination ARB and ACEI users [8]. These
findings for cancer risk were further investigated in large
population-based observational studies [9-12] which,
although generally negative, observed small increases in
cancer risk, for instance, for breast and prostate cancer in
ARB users [12] and lung cancer in ACEI users [11].
These results, and particularly the increases in fatal
cancer observed in the 2003 ARB trial [4], raise ques-
tions about the safety of ACEI and ARB use in cancer
patients. Despite these findings, there have not been any
studies which have investigated ARB use separately after
cancer diagnosis and cancer progression in prostate or
colorectal cancer patients and only two studies have
investigated the specific association between ARB use
and cancer progression in breast cancer patients [13,14].
ACEIs and cancer progression has also received little atten-
tion with only two studies of ACEI use in colorectal cancer
patients [15,16] and one in prostate cancer patients [17].
Five studies have investigated ACEI use in breast cancer pa-
tients and cancer progression but have reached conflicting
results [13,14,18-20]. Further investigation of ACEIs and
ARBs and cancer progression is, therefore, warranted.
This study investigated whether ACEI or ARB use after
diagnosis of breast, colorectal or prostate cancer was asso-
ciated with increased cancer-specific, or all cause, mortality
in large population-based cohorts of cancer patients.
Methods
Study design
Cohort studies were conducted utilizing linkages between
the English National Cancer Data Repository (NCDR), the
UK Clinical Practice Research Datalink (CPRD) and the
Office of National Statistics (ONS) death registrations.
The NCDR data include date and site of primary cancer
diagnosis and clinical data, such as stage and treatment.
The CPRD is the world’s largest database of longitudinal
patient records comprising around 8% of the UK popula-
tion and includes demographic information, clinical diag-
noses and prescription data which is of documented high
quality [21,22]. Ethical approval for all observational
research using CPRD data has been obtained from a
multicenter research ethics committee [23]. Linkages
between the datasets were conducted using a deter-
ministic algorithm based upon National Health Service
(NHS) number, gender, date of birth and postcode. Patients
were included in the cohorts if they had a CPRD diag-
nosis code for breast (women only), colorectal or prostate
cancer which was confirmed by NCDR cancer diagnosis
(based upon International Classification of Diseases (ICD)
codes of C50 for breast cancer, C61 for prostate cancer,
and C18, C19 and C20 for colorectal cancer) from 1998 to
2006. Cancer patients with previous NCDR cancer diagno-
sis, apart from in situ neoplasms and non-melanoma skin
cancers, were excluded. Cancer patients were also excluded
if the date of cancer diagnosis preceded CPRD research
quality records. Date and cause of death up to 2011 were
taken from ONS. Analysis was restricted to individuals with
available ONS mortality data from cancer diagnosis.
ACEI\ARB identification
ACEIs and ARBs were defined as all agents within the two
drug classes according to the British National Formulary
[24] (BNF, chapters 2.5.5.1 and 2.5.5.2, respectively). ACEI
and ARB prescriptions within the cohorts from CPRD
prescribing data were counted and converted to daily de-
fined doses (DDD) on the basis of the quantity and strength
(as defined by the World Health Organization [25]). A
quantity of 28 tablets was assumed for approximately 2% of
prescriptions where quantity was missing or inconsistent.
Medication usage was ascertained in the exposure period
described later.
Potential confounders
Data available from the NCDR included stage, histological
grade, Gleason score (for prostate cancer), surgery, chemo-
therapy and radiotherapy in the six months after diagnosis.
Gleason score was converted to grade to increase com-
pleteness [26]. General practitioner (GP) prescribing data
were used to determine hormone therapy in the first six
months after cancer diagnosis including androgen therapy
for prostate cancer (BNF chapter 8.3.4.2, including gonador-
elin analogues and anti-androgens) and tamoxifen and aro-
matase inhibitors for breast cancer (BNF chapter 8.3.4.1).
Breast and prostate cancer patients were excluded if
hormone therapy preceded cancer diagnosis by eight
weeks. In breast cancer patients, hormone replacement
therapy (HRT) for estrogen and progestogens (BNF chapters
6.4.1. and 6.4.2.) was determined prior to diagnosis. Low
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dose aspirin and statin use were taken from GP pre-
scription records. Smoking, alcohol intake and body
mass index (BMI) were determined from the closest GP
record prior to cancer diagnosis (records older than ten
years were ignored). Comorbidities were determined from
GP diagnosis codes on the basis of diagnoses contributing
to a recent adaptation of the Charlson comorbidity index
for GPRD [27].
Data analysis
The cancer cohorts were initially analyzed using a time
matched nested case–control approach, a common ap-
proach, for example [28], which accounts for immortal time
bias [29] without requiring complicated statistical tech-
niques [30] with minimal loss of precision [31], and a time
varying covariate approach, described later. Breast cancer
cases were members who had died due to breast cancer
(with an ICD code of C50 as the underlying cause of death)
and these were matched on age (in five year intervals) and
year of cancer diagnosis to five risk-set controls who lived
at least as long after their cancer diagnosis. Correspond-
ing analyses were conducted for colorectal cancer cases
(ICD codes of C18, C19, C20, C21 or C26 as their under-
lying cause of death) who were matched to risk-set controls
on gender, site (colon or rectal), age (in five year intervals)
and year of cancer diagnosis (in two year intervals) and
prostate cancer cases (with ICD codes of C61 as their
underlying cause of death) who were matched to risk
set controls on age (in five year intervals) and year of
cancer diagnosis.
The exposure period (for identification of post-diagnostic
medication usage) in cases was the period from cancer
diagnosis until six months prior to cancer-specific death.
The exposure period in the controls was fixed to be the
same duration as that of their matched cases and began
at the date of cancer diagnosis in the control. The ex-
posure period did not include prescriptions in the six
month period prior to death as these may reflect end
of life treatment or increased exposure to healthcare
professionals (sensitivity analyses investigated increasing
this to 12 months). Analyses were restricted to individuals
with at least one year of follow-up after cancer diagnosis.
Conditional logistic regression was used to estimate the
odds of death from cancer in cancer patients prescribed
one or more ACEIs in the exposure period compared to
those with none and corresponding odds ratios (ORs) and
95% confidence intervals (95% CIs) were determined before
and after adjustment for potential confounders. Similar
analyses were conducted by duration of medication usage
(investigating individuals prescribed over 365 DDDs of
ACEIs in the exposure period equivalent to one year of
usage). These analyses were repeated for ARBs. An analysis
of all-cause mortality was also conducted in which cancer
patients who died from any-cause were matched to risk-set
controls (using the same matching criteria as in the cancer-
specific analyses) and conditional logistic regression models
were applied as described previously. A secondary analysis
was conducted to investigate pre-diagnostic ACEI/ARB
use. Two sensitivity analyses were conducted which re-
stricted the non-user group to patients with more similar
indications. In one analysis, the cancer cohorts were first
restricted to individuals using any antihypertensive medica-
tions in the year prior to cancer diagnosis (including di-
uretics, vasodilator antihypertensive drugs, centrally acting
antihypertensive drugs, alpha-adrenoceptor blocking drugs,
beta-blockers, ACEIs, ARBs, renin inhibitors, and calcium
channel blockers) and the analysis was conducted as previ-
ously. In the other sensitivity analysis, the full cohort was
used as in the main analysis but ORs were calculated com-
paring ACEI/ARB users in the exposure period not to
ACEI/ARB non-users in the exposure period (as in the
main analysis) but to ACEI/ARB non-users who had used
at least one other antihypertensive medication in the expos-
ure period. Sensitivity analyses were also conducted add-
itionally adjusting for other antihypertensive use and in
breast and prostate cancer patients, adjusting for hormone
therapy at any time after diagnosis (not just in the first six
months after diagnosis as in the main analysis). A sensitivity
analyses was conducted in prostate cancer patients adjust-
ing for Gleason score and in breast cancer patients re-
stricted to cancer registries with high rates of available
stage (overall, over 85% complete). Stratified analyses were
conducted by stage (for colorectal and breast cancer), sex
(for colorectal) and site (for colorectal cancer). Stratified
analyses were conducted after re-matching cases to controls
within strata. Interaction tests were used to compare associ-
ations between strata [32].
Additionally, the cancer cohort was analyzed, without
conversion to case–control data, applying survival ana-
lysis to investigate ACEI/ARB exposure as a time vary-
ing covariate (individuals were considered non-users
prior to use and users after a lag of six months after first
use, to mimic the case–control analysis) [29]. A similar
dose response analysis was conducted with individuals
considered non-users prior to six months after first
use, a short term user between six months after first
use and six months after 365 DDDs and a longer term
user after this time. A separate analysis was conducted
additionally adjusting for competing risk of deaths
using Fine and Gray’s proportional subhazards model
(not shown, as results similar) [33].
A pre-study power calculation based upon 15% ACEI
use and predicted numbers suggested the study would
have over 80% power to detect an OR of 1.20 for cancer-
specific mortality in patients receiving ACEIs in each of
the cancer cohorts (breast, colorectal, prostate). More ac-
curately, based upon the final numbers (shown in Table 1)
and ACEI and ARB use (shown in Table 2), the study had
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Table 1 Characteristics of cancer patients who die from cancer (cases) compared with controls, by cancer site
Breast cancer Colorectal cancer Prostate cancer
Cases Controls P Cases Controls P Cases Controls P
number (%) number (%) number (%) number (%) number (%) number (%)
Year of diagnosis
1998 to 2000 500 (35) 2,466 (35) N.A. 379 (25) 1,842 (25) N.A. 396 (33) 1,941 (33) N.A.
2001 to 2003 518 (36) 2,570 (36) 564 (37) 2,721 (37) 461 (39) 2,281 (39)
2003 to 2006 417 (29) 2,070 (29) 568 (38) 2,728 (37) 327 (28) 1,627 (28)
Age at diagnosis (years)
<50 339 (24) 1,667 (23) N.A. 90 (6) 330 (5) N.A. 6 (1) 20 (0) N.A.
50 to 59 286 (20) 1,430 (20) 226 (15) 1,117 (15) 71 (6) 351(6)
60 to 69 273 (19) 1,365 (19) 401 (27) 2,001 (27) 280 (24) 1,400 (24)
70 to 79 318 (22) 1,588 (22) 496 (33) 2,472 (34) 532 (45) 2,660 (45)
≥ 80 219 (15) 1,056 (15) 298 (20) 1,371 (19) 295 (25) 1,418 (24)
Male 0 (0) 0 (0) N.A. 871 (58) 4,231 (58) N.A. 1,184(100) 5,849 (100) N.A.
Exposure period (years):
Mean (sd) 3.9 (2.3) 3.9 (2.3) N.A. 2.8 (1.6) 2.9 (1.7) N.A. 3.8 (2.2) 3.7 (2.2) N.A.
Range 1.0 to 12.8 1.0 to 12.8 N.A. 1.0 to 10.5 1.0 to 10.5 N.A. 1.0 to 11.9 1.0 to 11.9
Stage:1 72 (11) 1,471 (43) <0.001 61 (6) 1,044 (18) <0.001
2 402 (61) 1,676 (49) 275 (25) 2,496 (44)
3 116 (18) 220 (6) 558 (51) 1,981 (35)
4 64 (10) 40 (1) 203 (19) 195 (3)
Missing 781 3,699 414 1,575
Grade:Well 54 (6) 751 (19) 81 (7) 562 (9) <0.001 34 (4) 538 (13) <0.001
Moderate 377 (41) 1,900 (49) 889 (75) 4,894 (78) 217 (28) 2,067 (48)
Poor 492 (53) 1,217 (31) 208 (17) 818 (13) 516 (67) 1,683 (39)
Missing 512 3,280 333 1017 417 1561
Treatment within six months
of diagnosis
Chemotherapy 573 (40) 1,611 (23) <0.001 651 (43) 1,916 (26) <0.001 49 (4) 137 (2) <0.001
Radiotherapy 700 (49) 3,355 (47) 0.22 302 (20) 1,066 (15) <0.001 246 (21) 1,276 (22) 0.48
Surgery 1,087 (76) 5,982 (84) <0.001 1,214 (80) 65,15 (89) <0.001
Tamoxifen therapy 709 (49) 4,610 (65) <0.001
Androgen therapy 976 (82) 3,450 (59) <0.001
Radical prostatectomya 20 (2) 331 (8) <0.001
Smoking prior to diagnosis 0.03 0.01 <0.001
Non-smoker 710 (60) 3,827 (64) 640 (51) 3,138 (52) 453 (47) 2,541 (52)
Ex-smoker 226 (19) 1,072 (18) 365 (29) 1,885 (31) 331 (34) 1,660 (34)
Current smoker 249 (21) 1,094 (18) 249 (20) 983 (16) 185 (19) 674 (14)
Missing 250 1,113 257 1285 215 974
BMI prior to diagnosis 0.01 0.66 0.05
Mean (sd) 26.6 (5.5) 26.2 (5.1) 26.5 (4.7) 26.6 (4.8) 26.4 (4.0) 26.1 (3.7)
Missing 386 1,633 412 1,810 302 1,362
Alcohol prior to diagnosis 0.58 0.47 0.37
Alcohol consumer 831 (80) 4,333 (81) 950 (87) 4,585 (86) 791 (89) 4,047 (90)
Missing 401 1,779 420 1,977 298 1366
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approximately 80% power to detect, at the 5% significance
level, an OR for cancer-specific mortality in ACEI users
of 1.25 and for ARB users of 1.35 in each of the cancer
cohorts. Statistical analyses were conducted in STATA
11 (StataCorp, College Station, Texas).
Results
Patient cohorts
Figure 1 shows the selection of the final cohorts. The
average follow-up (in those not dying) was six years
(range one to thirteen years) in each of the three cohorts.
The crude rate of cancer-specific death was 28.0 per 1,000
person years in the breast cancer cohort (based upon 1,440
breast cancer-specific deaths in 51,507 person years), 78.5
per 1,000 person years in the colorectal cancer cohort
(based upon 1,528 colorectal cancer-specific deaths in
19,462 person years), and 41.2 per 1,000 person years in the
prostate cancer cohort (based upon 1,194 prostate cancer-
specific deaths in 28,970 person years). These cohorts were
converted to case–control data for the cancer-specific mor-
tality analysis with 1,435 breast, 1,511 colorectal and 1,184
prostate cases (cancer-specific deaths) and 7,106 breast,
7,291 colorectal and 5,849 prostate risk-set controls.
Patient characteristics
Table 1 shows characteristics of cancer-specific deaths
(cases) and controls. The average time to death and, hence,
the end of the exposure period was 3.9, 2.8 and 3.8 years
for breast, colorectal and prostate cancer, respectively.
Cancer-specific deaths (cases) had higher stage, higher
histological grade, more chemotherapy and less sur-
gery. A higher proportion of cases had radiotherapy for
colorectal but not breast or prostate cancer. Hormone
therapy was less frequent in breast cancer cases but
more frequent in prostate cancer cases. Smoking rates were
slightly higher in cases. Rates of comorbidities, alcohol
consumption and BMI levels prior to diagnosis were
generally similar between cases and controls (Table 1).
ACEI/ARB use and mortality in breast cancer patients
In breast cancer patients (Table 2), the ACEI prescriptions
after diagnosis were similar in those dying from cancer
(cases) compared with controls (16.9% versus 16.4%,
respectively; OR = 1.04, 95% CI 0.88, 1.22). Adjustment
for potential confounders did not alter this OR markedly
(OR = 1.06, 95% CI 0.89, 1.27). Similarly, no associations
were observed between cancer-specific mortality and ARB
use (adjusted OR = 1.06, 95% CI 0.84, 1.35). These findings
were little altered after adjustment for stage and were fairly
consistent across sensitivity analyses (shown in Table 3).
No associations were observed with pre-diagnostic
use (Table 3). Finally, analyses of post-diagnostic ACEI
(adjusted OR = 1.04, 95% CI 0.92, 1.19) and ARB (adjusted
OR = 0.96, 95% CI 0.81, 1.14) use and all-cause mortality
showed little evidence of associations (Table 4).
ACEI/ARB use and mortality in colorectal cancer patients
In colorectal cancer patients (Table 2), there was some
evidence of a reduction in cancer-specific mortality in
patients prescribed an ACEI (OR = 0.79, 95% CI 0.69, 0.92)
which was little altered after adjustment for confounders
(adjusted OR = 0.78, 95% CI 0.66, 0.92), but a clear dose
response association was not apparent as there was little
evidence of protective effects in those using more than
365 DDDs of ACEI (adjusted OR = 0.84 95% CI 0.68, 1.03).
There was little evidence of an association between ARBs
and cancer-specific mortality (adjusted OR = 0.82 95% CI
0.64, 1.07). Additional adjustment for stage little altered
these estimates. Sensitivity analyses (Table 5) produced
fairly consistent results for ARBs. Any protective associ-
ation for ACEIs were attenuated when prescriptions in the
year prior to death were removed (adjusted OR = 0.83 95%
Table 1 Characteristics of cancer patients who die from cancer (cases) compared with controls, by cancer site
(Continued)
Comorbidity (prior to diagnosis
or during follow-up time)
Cerebrovascular 89 (6) 383 (5) 0.53 117 (8) 493 (7) 0.19 124 (10) 509 (9) 0.07
C.P.D. 264 (18) 1,247 (18) 0.60 236 (16) 1295 (18) 0.06 229 (19) 1,110 (19) 0.80
C.H.D. 60 (4) 249 (4) 0.68 91 (6) 367 (5) 0.13 108 (9) 395 (7) 0.01
Diabetes 126 (9) 468 (7) 0.02 192 (13) 866 (12) 0.21 141 (12) 619 (11) 0.17
Myocardial infarction 26 (2) 148 (2) 0.74 104 (7) 454 (6) 0.32 130 (11) 522 (9) 0.03
Peptic ulcer disease 39 (3) 184 (3) 0.79 111 (7) 477 (7) 0.19 77 (7) 440 (8) 0.18
P.V.D. 51 (4) 165 (2) 0.003 64 (4) 331 (5) 0.70 113 (10) 396 (7) 0.001
Renal disease 78 (5) 382 (5) 0.92 107 (7) 478 (7) 0.45 138 (12) 509 (9) 0.001
Rheumatological 76 (5) 330 (5) 0.35 55 (4) 272 (4) 0.82 37 (3) 287 (5) 0.01
aExcludes cancer registries without available data. C.P.D., chronic pulmonary disease; C.H.D., congestive heart disease; N.A., not applicable; P.V.D., peripheral
vascular disease; sd, standard deviation.
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Table 2 Association between post-diagnostic exposure to ACEIs and ARBS and cancer specific death, by cancer site
Post-diagnostic
medication usage
All cancer patients Cancer patients with available stage/gradec
Cancer specific
deaths number (%)
Controls
number (%)
Unadjusted
OR (95% CI)
P (trenda) Adjustedb
OR (95% CI)
P (trenda) Unadjusted
OR (95% CI)
P (trenda) Fully adjusted
OR (95% CI)d
P (trenda)
Breast cancer
ACEI
0 (non-user) 1,192 (83.1) 5,938 (83.6) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 243 (16.9) 1,168 (16.4) 1.04 (0.88, 1.22) 0.65 1.06 (0.89, 1.27) 0.52 0.96 (0.76, 1.21) 0.72 0.83 (0.63, 1.09) 0.18
(0.50) (0.32) (0.88) (0.47)
1to 365 DDDs 92 (6.4) 469 (6.6) 0.97 (0.77, 1.23) 0.80 0.96 (0.75, 1.24) 0.78 0.88 (0.61, 1.27) 0.49 0.65 (0.43, 0.99) 0.04
≥365 DDDs 151 (10.5) 699 (9.8) 1.08 (0.89, 1.32) 0.42 1.14 (0.92, 1.41) 0.25 1.01 (0.76, 1.33) 0.96 0.96 (0.69, 1.34) 0.82
ARB
0 (non-user) 1,333 (92.9) 6,602 (92.9) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 102 (7.1) 504 (7.1) 1.00 (0.80, 1.26) 0.98 1.06 (0.84, 1.35) 0.62 1.03 (0.84, 1.25) 0.80 0.94 (0.65, 1.37) 0.75
(0.99) (0.57) (0.69) (0.85)
1 to 365 DDDs 33 (2.3) 160 (2.3) 1.02 (0.70, 1.51) 0.87 1.01 (0.68, 1.51) 0.96 1.04 (0.58, 1.87) 0.90 0.84 (0.44, 1.61) 0.59
≥365 DDDs 69 (4.8) 344 (4.8) 0.99 (0.75, 1.30) 0.95 1.09 (0.82, 1.45) 0.55 1.08 (0.73, 1.60) 0.70 0.99 (0.64, 1.52) 0.95
Colorectal cancer
ACEI
0 (non-user) 1,231 (81.5) 5,660 (77.6) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 280 (18.5) 1,631 (22.4) 0.79 (0.69, 0.92) 0.002 0.78 (0.66, 0.92) 0.003 0.75 (0.63, 0.89) 0.001 0.76 (0.62, 0.93) 0.01
(0.01) (0.02) (0.005) (0.02)
1 to 365 DDDs 113 (7.5) 729 (10.0) 0.72 (0.59, 0.89) 0.002 0.71 (0.57, 0.89) 0.03 0.69 (0.54, 0.90) 0.005 0.71 (0.53, 0.94) 0.02
≥365 DDDs 167 (11.1) 902 (12.4) 0.85 (0.71, 1.02) 0.09 0.84 (0.68, 1.03) 0.10 0.80 (0.64, 0.98) 0.03 0.80 (0.63, 1.02) 0.07
ARB
0 (non-user) 1,428 (94.5) 6,811 (93.4) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 83 (5.5) 480 (6.6) 0.84 (0.66, 1.07) 0.15 0.82 (0.64, 1.07) 0.14 0.91 (0.76, 1.08) 0.29 0.80 (0.59, 1.09) 0.16
(0.41) (0.94) (0.26) (0.66)
1 to 365 DDDs 29 (1.9) 221 (3.0) 0.64 (0.43, 0.95) 0.03 0.63 (0.42, 0.94) 0.03 0.51 (0.31, 0.83) 0.01 0.61 (0.37, 1.03) 0.06
≥365 DDDs 54 (3.6) 259 (3.6) 1.00 (0.74, 1.36) 0.98 1.00 (0.72, 1.37) 0.98 0.98 (0.69, 1.38) 0.89 0.93 (0.64, 1.36) 0.72
Prostate cancer
ACEI
0 (non-user) 848 (71.6) 4,145 (70.9) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 336 (28.4) 1,704 (29.1) 0.96 (0.83, 1.10) 0.55 0.78 (0.66, 0.92) 0.003 0.98 (0.82, 1.17) 0.80 0.82 (0.67, 1.02) 0.07
(0.47) (0.003) (0.85) (0.11)
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Table 2 Association between post-diagnostic exposure to ACEIs and ARBS and cancer specific death, by cancer site (Continued)
1 to 365 DDDs 118 (10.0) 572 (9.8) 1.00 (0.81, 1.24) 0.99 0.83 (0.66, 1.04) 0.11 0.96 (0.74, 1.26) 0.79 0.80 (0.59, 1.07) 0.14
≥365 DDDs 218 (18.4) 1,132 (19.4) 0.94 (0.79, 1.11) 0.44 0.75 (0.62, 0.91) 0.003 0.98 (0.80, 1.21) 0.88 0.84 (0.66, 1.07) 0.16
ARB
0 (non-user) 1,103 (93.2) 5,384 (92.1) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 81 (6.8) 465 (8.0) 0.86 (0.67, 1.10) 0.22 0.79 (0.61,1.03) 0.08 0.93 (0.70, 1.23) 0.62 0.82 (0.61, 1.11) 0.21
(0.16) (0.06) (0.75) (0.26)
1 to 365 DDDs 30 (2.5) 153 (2.6) 0.97 (0.65, 1.44) 0.88 0.88 (0.58, 1.33) 0.55 0.84 (0.52, 1.36) 0.48 0.77 (0.46, 1.29) 0.33
≥365 DDDs 51 (4.3) 312 (5.3) 0.80 (0.59, 1.09) 0.15 0.74 (0.54, 1.02) 0.07 0.98 (0.70, 1.36) 0.90 0.84 (0.59, 1.21) 0.36
aTests for trend from conditional logistic regression model based upon categories of DDDs (0, 1 to 365, ≥365 DDDs coded as 0, 1, 2, respectively). bAll models include surgery (within six months of diagnosis),
chemotherapy (within six months), radiotherapy (within six months), low dose aspirin (during exposure period), statins (during exposure period), comorbidities (pre-diagnosis or during exposure period, including
myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral vascular disease, renal disease, peptic ulcer disease and diabetes), and smoking (pre-diagnosis, with
missing included as a category). The breast cancer model additionally includes tamoxifen (within six months), aromatase inhibitors (within six months), hormone replacement therapy (pre-diagnosis). The prostate
cancer model additionally includes androgen therapy (within six months). cAnalysis includes 1,093 cases and 5,231 controls in colorectal cancer patients with available stage, 648 cases and 3,193 controls in breast
cancer patients with available stage and 766 cases and 3,777 controls in prostate cancer patients with available grade. dAdditionally adjusted for stage in colorectal cancer patients and breast cancer patients and
adjusted for grade in prostate cancer patients. ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CI, confidence interval; DDDs, daily defined doses; OR, odds ratio.
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CI 0.67, 1.03) or when the analysis was restricted to users
of any antihypertensive medication in the year prior to
cancer diagnosis (adjusted OR = 0.83 95% CI 0.65, 1.07).
In early stage colorectal cancer a more marked reduction
in cancer specific mortality was observed with ACEI
use (adjusted OR = 0.54 95% CI 0.38, 0.77) compared
with later stage disease (adjusted OR = 0.86, 95% CI
0.68, 1.10; P for interaction = 0.03). In general, any pro-
tective associations were less marked when using the
time varying covariate approach but other sensitivity
analyses for ACEIs were similar to the main finding.
No associations were observed between cancer-specific
mortality and pre-diagnostic ACEI and ARB use (Table 3).
Finally, there was little evidence of associations with
all-cause mortality and ACEI (adjusted OR = 0.90, 95% CI
0.79, 1.02) or ARB (adjusted OR = 0.94, 95% CI 0.78, 1.13)
use after cancer diagnosis (Table 4).
ACEI/ARB use and mortality in prostate cancer patients
In prostate cancer patients (Table 2), there was no evidence
of an increase in cancer-specific mortality in ACEI users
(adjusted OR = 0.78, 95% CI 0.66, 0.92) or ARB users
(adjusted OR= 0.79, 95% CI 0.61, 1.03). Additionally, adjust-
ing for grade little altered the point estimates although the
protective association with ACEIs was no longer significant
(fully adjusted OR = 0.82 95% CI 0.67, 1.02). The associa-
tions for ARB use were fairly consistent across sensitiv-
ity analyses (Table 6). The protective association with
ACEIs was more marked when restricting the analysis
to antihypertensive users during the exposure period
(adjusted OR = 0.78 95% CI 0.63, 0.96) and when adjusting
for other antihypertensive use (adjusted OR = 0.74 95% CI
0.60, 0.92), but were attenuated in most other sensitivity
analyses particularly when prescriptions in the year prior to
death were removed (adjusted OR = 0.88 95% CI 0.70, 1.09)
and in time-varying covariate analyses (adjusted hazard
ratio (HR) = 0.90 95% CI 0.76, 1.07). There was little
evidence of a reduction in all-cause mortality in ACEI
users (adjusted OR = 0.91, 95% CI 0.82, 1.03) or ARB
users (adjusted OR = 0.85, 95% CI 0.72, 1.01) after cancer
diagnosis (Table 4).
Discussion
Overall, we found no evidence of increased risks of
cancer-specific or all-cause mortality in breast, colorectal
or prostate cancer patients using ACEIs or ARBs after
cancer diagnosis. There was some evidence of reductions
in the risk of cancer-specific mortality in colorectal and
1,435 cancer-specific deaths (cases)  1,511 cancer-specific deaths 1,184 cancer-specific deaths
7,106 matched controls 7,291 matched controls 5,849 matched controls
(5 cases had no available match) (17 cases had no available match)        (10 cases had no available match)
2,258 all-cause deaths 2,101 all-cause deaths 2,197 all-cause deaths
11,154 matched controls 10,107 matched controls 10,838 matched controls
(13 cases had no available match) (33 cases had no available match)        (16 cases no available match)
Patients diagnosed 1998-2007 with CPRD 
coverage and no previous cancer. 
Breast cancer Colorectal cancer Prostate cancer 
11,863 breast cancer patients 7,081 colorectal cancer patients 8,128 prostate cancer patients 
After excluding patients where cancer diagnosis 
preceded CPRD research quality records.* 10,969 breast cancer patients 6,666 colorectal cancer patients 7,495 prostate cancer patients 
After excluding patients where death 
registration data unavailable.† 10,853 breast cancer patients 6,540 colorectal cancer patients 7,388 prostate cancer patients 
After excluding patients with <1 year follow-
up. 9,971 breast cancer patients 4,762 colorectal cancer patients 6,513 prostate cancer patients 
After excluding patients where hormone therapy 
preceded cancer diagnosis by 8 weeks.‡ 9,814 breast cancer patients 4,762 colorectal cancer patients 6,339 prostate cancer patients 
Final cohort for analysis. 9,814 breast cancer patients 4,762 colorectal cancer patients 6,339 prostate cancer patients 
1,440 cancer specific deaths 1,528 cancer specific deaths 1,194 cancer specific deaths
Data for analysis after 
conversion to case-
control data.
2,271 all-cause deaths 2,134 all-cause deaths 2,213 all-cause deaths
Cancer-specific 
mortality analysis
All-cause mortality 
analysis
* Patients excluded because cancer diagnosis preceded CPRD research quality records, and therefore prescription records may not be complete from diagnosis. 
† Patients excluded because death registration data unavailable and therefore death and cause of death data would not be identified in this patients.  
‡ Patients excluded because hormone therapy records preceding cancer diagnosis suggests an incorrect diagnosis date, not applicable to colorectal cancer.   
Figure 1 Flow chart of selection of patients for inclusion in analysis, by cancer site.
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prostate cancer patients using ACEIs, but any protective
effects were weak in magnitude, were inconsistent across
sensitivity analyses and were not a priori stated and,
therefore, are difficult to interpret.
Strengths and weaknesses
The main strengths of our study were the large size
(including over 20,000 cancer patients and 4,000 cancer-
specific deaths) and the long duration of follow-up
(up to 13 years) which provided the ability to detect
relatively weak effects and to report narrow CIs which
rule out relatively small increases in risk. Our study
used GP prescribed drug information which captures
almost all ACEI and ARB use (which are only available by
prescription in the UK), eliminates the potential for recall
bias incurred by self–report and allows detailed temporal
associations to be explored. Consequently, our data reflect
GP prescriptions rather than drug consumption but
analyses of multiple prescriptions generally found similar
results, suggesting compliance may not impact our results
greatly. As with all observational studies we cannot exclude
residual or unknown confounding. We had robust data
on surgery, radiotherapy, chemotherapy, hormone ther-
apy, comorbidities and importantly stage for colorectal
and breast and Gleason score for prostate cancer, but
we had limited data on smoking and alcohol intake and
no information on socioeconomic status.
Comparison with previous studies
In prostate and colorectal cancer our study is the first
epidemiological study to investigate ARBs separately and
cancer progression and only three studies have investigated
Table 3 Sensitivity analyses for association between ACEIs and ARBS and cancer specific mortality in breast cancer patients
Cancer specific
deaths number
Controls
number
OR (95% CI) P OR (95% CI) P
ACEI user versus
non user
ARB user versus
non user
Breast cancer
Main analysis: diagnosis to six months prior to deatha 648 3,193 0.83 (0.63, 1.09) 0.18 0.94 (0.65, 1.37) 0.75
Diagnosis to 1 year prior to deathb 583 2,875 0.87 (0.65, 1.16) 0.33 0.87 (0.58, 1.30) 0.49
Restricted to users of any antihypertensive medicationc prior
to cancer diagnosisd
212 994 0.87 (0.60, 1.25) 0.44 1.36 (0.85, 2.16) 0.20
Comparison group restricted to users of any antihypertensive
in exposure periodc
361 1,624 0.79 (0.59, 1.05) 0.10 0.92 (0.63, 1.34) 0.67
Additionally adjusting for other antihypertensivese 648 3,193 0.79 (0.60, 1.06) 0.12 0.90 (0.61, 1.33) 0.60
Additionally adjusting for hormone therapy any time after diagnosisf 648 3,193 0.80 (0.60, 1.05) 0.11 0.98 (0.66, 1.44) 0.91
≥730 DDDs versus 0 DDDs (non-user) 648 3,193 1.06 (0.74, 1.52) 0.75 0.99 (0.64, 1.52) 0.95
Restricted to cancer registries with stage data available for over
85% of patients
487 1,911 0.84 (0.59, 1.18) 0.31 1.33 (0.81, 2.17) 0.25
Stage 1 and 2g 469 2,313 0.95 (0.68, 1.32) 0.75 1.14 (0.73, 1.81) 0.56
Stage 3 and 4g 161 531 0.83 (0.46, 1.51) 0.54 2.37 (1.05, 5.35) 0.04
Pre-diagnostic useh 695 3,413 0.86 (0.61, 1.20) 0.37 1.06 (0.65, 1.72) 0.82
Time varying covariate analysisi 656 4,164
≥1 DDDs versus 0 DDDs (non-user) 0.97 (0.77, 1.21) 0.76 1.20 (0.89, 1.62) 0.23
1to 365 DDDs versus 0 DDDs (non-user) 0.90 (0.65, 1.25) 0.52 0.94 (0.55, 1.60) 0.81
≥365 DDDs versus 0 DDDs (non-user) 1.01 (0.77, 1.32) 0.93 1.35 (0.96, 1.91) 0.09
aExcept where otherwise stated analysis investigates medications from diagnosis to six months prior to death/index date and models include surgery (within six
months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), low dose aspirin (during exposure period), statins (during exposure period),
comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease,
peripheral vascular disease, renal disease, peptic ulcer disease and diabetes), and smoking (pre-diagnosis, with missing included as a category), tamoxifen (within six months),
aromatase inhibitors (within six months), hormone replacement therapy (pre-diagnosis) and stage. bRestricted to individuals surviving more than 1.5 years. cAntihypertensive
medications include beta-blockers, diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, ACEIs, ARBs, renin
inhibitors, and calcium channel blockers. dRestricted to individuals with >1 year of records prior to cancer diagnosis and pre-diagnostic use considered antihypertensive
use in that year, excluding deaths in the year after cancer diagnosis. eModels include all variables in aand additionally include calcium channel blockers, diuretics and
beta-blockers. fModels include all variables in abut tamoxifen and aromatase inhibitors were determined at any time after diagnosis in the exposure period. gStratified
analyses were conducted after re-matching controls to cases within strata; due to non-availability of matches overall numbers in subgroups may not be identical to
numbers presented in Table 1. hRestricted to individuals with >1 year of records prior to cancer diagnosis and pre-diagnostic use considered ACEI/ARB use in that year,
not excluding deaths in the year after cancer diagnosis. iReported estimates are adjusted hazard ratios and 95% CIs, model includes age at diagnosis, year of diagnosis,
surgery (within six months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), statins (during exposure period, as a time varying
covariate), comorbidities (pre-diagnosis including, myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral
vascular disease, renal disease, peptic ulcer disease and diabetes) and stage. ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers;
CI, confidence interval; DDDs, daily defined doses; OR, odds ratio.
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Table 4 Association between post-diagnostic exposure to ACEIs and ARBS and all-cause mortality, by cancer site
Post-diagnostic
medication usage
All cancer patients Cancer patients with available stage/gradeb
All-cause deaths
number (%)
Controls
number (%)
Unadjusted
OR (95% CI)
P (trendd) Adjusteda
OR (95% CI)
P (trendd) Unadjusted
OR (95% CI)
P (trendd) Fully adjusted
OR (95% CI)c
P (trendd)
Breast cancer
ACEI
0 (non-user) 1,749 (77.5) 8,948 (80.2) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 509 (22.5) 2,206 (19.8) 1.19 (1.06, 1.34) 0.003 1.04 (0.92, 1.19) 0.51 1.19 (1.00, 1.41) 0.05 0.93 (0.76, 1.14) 0.49
(0.01) (0.60) (0.09) (0.37)
1 to 365 DDDs 193 (8.6) 821 (8.6) 1.20 (1.02, 1.42) 0.03 1.06 (0.89, 1.27) 0.52 1.26 (0.97, 1.62) 0.08 1.00 (0.76, 1.34) 0.97
≥365 DDDs 316 (14.0) 1,385 (12.4) 1.18 (1.03, 1.36) 0.02 1.03 (0.89, 1.20) 0.68 1.15 (0.94, 1.41) 0.17 0.89 (0.71, 1.13) 0.34
ARB
0 (non-user) 2,057 (91.1) 10,161 (91.1) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 201 (8.9) 993 (8.9) 1.00 (0.85, 1.18) 0.99 0.96 (0.81, 1.14) 0.62 0.91 (0.71, 1.16) 0.45 0.79 (0.60 ,1.03) 0.08
(0.85) (0.80) (0.69) (0.18)
1 to 365 DDDs 64 (2.8) 338 (3.0) 0.93 (0.70, 1.22) 0.59 0.88 (0.66, 1.17) 0.37 0.73 (0.47, 1.15) 0.18 0.62 (0.39, 1.00) 0.05
≥365 DDDs 137 (6.1) 655 (5.9) 1.04 (0.85, 1.26) 0.71 1.00 (0.82, 1.23) 0.99 1.00 (0.75, 1.33) 0.99 0.87 (0.64, 1.19) 0.38
Colorectal cancer
ACEI
0 (non-user) 1,596 (76.0) 7,578 (75.0) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 505 (24.0) 2,529 (25.0) 0.96 (0.85, 1.07) 0.44 0.90 (0.79, 1.02) 0.10 0.94 (0.82, 1.07) 0.36 0.89 (0.76, 1.03) 0.12
(0.31) (0.05) (0.38) (0.10)
1 to 365 DDDs 206 (9.8) 985 (9.8) 1.00 (0.86, 1.18) 0.95 0.95 (0.80, 1.13) 0.58 0.94 (0.78, 1.14) 0.55 0.92 (0.75, 1.13) 0.41
≥365 DDDs 299 (14.2) 1,544 (15.3) 0.92 (0.80, 1.06) 0.27 0.85 (0.73, 1.00) 0.05 0.94 (0.80, 1.10) 0.43 0.86 (0.72, 1.04) 0.11
ARB
0 (non-user) 1,939 (92.3) 9,294 (92.0) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 162 (7.8) 813 (8.0) 0.97 (0.82, 1.16) 0.78 0.94 (0.78, 1.13) 0.50 1.01 (0.82, 1.23) 0.95 1.02 (0.82, 1.26) 0.88
(0.88) (0.86) (0.66) (0.72)
1 to 365 DDDs 59 (2.8) 344 (3.4) 0.84 (0.64, 1.12) 0.24 0.80 (0.60, 1.06) 0.12 0.85 (0.61, 1.19) 0.35 0.92 (0.65, 1.31) 0.66
≥365 DDDs 103 (4.9) 469 (4.6) 1.07 (0.86, 1.34) 0.54 1.05 (0.83, 1.32) 0.70 1.11 (0.86, 1.41) 0.42 1.07 (0.83, 1.39) 0.60
Prostate cancer
ACEI
0 (non-user) 1,463 (66.6) 7,512 (69.3) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 734 (33.4) 3,326 (30.7) 1.14 (1.03, 1.26) 0.01 0.91 (0.82, 1.03) 0.13 1.09 (0.97, 1.23) 0.15 0.88 (0.76, 1.00) 0.06
(0.04) (0.05) (0.13) (0.07)
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Table 4 Association between post-diagnostic exposure to ACEIs and ARBS and all-cause mortality, by cancer site (Continued)
1 to 365 DDDs 258 (11.7) 1,098 (10.1) 1.20 (1.04, 1.40) 0.01 1.00 (0.85, 1.17) 0.96 1.06 (0.89, 1.27) 0.53 0.88 (0.73, 1.07) 0.20
≥365 DDDs 476 (21.7) 2,228 (20.6) 1.11 (0.98, 1.24) 0.09 0.87 (0.76, 0.99) 0.04 1.11 (0.97, 1.27) 0.14 0.87 (0.75, 1.02) 0.09
ARB
0 (non-user) 2,002 (91.1) 9,873 (91.1) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.) 1.00 (ref. cat.)
≥1 DDD (user) 195 (8.9) 965 (8.9) 1.00 (0.85, 1.18) 0.98 0.85 (0.72, 1.01) 0.06 1.08 (0.89, 1.30) 0.45 0.92 (0.75, 1.12) 0.39
(0.99) (0.07) (0.33) (0.56)
1 to 365 DDDs 61 (2.8) 297 (2.7) 1.02 (0.77, 1.35) 0.89 0.86 (0.64, 1.15) 0.32 0.95 (0.68, 1.33) 0.77 0.81 (0.57, 1.14) 0.26
≥365 DDDs 134 (6.1) 668 (6.2) 0.99 (0.82, 1.21) 0.95 0.84 (0.69, 1.03) 0.10 1.14 (0.91, 1.43) 0.26 0.97 (0.76, 1.23) 0.81
aAll models include surgery (within six months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), low dose aspirin (during exposure period), statins (during exposure period),
comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral vascular disease, renal disease, peptic
ulcer disease and diabetes), and smoking (pre-diagnosis, with missing included as a category). The breast cancer model additionally includes tamoxifen (within six months), aromatase inhibitors (within six months),
hormone replacement therapy (pre-diagnosis). The prostate cancer model additionally includes androgen therapy (within six months). bAnalysis includes 1,558 cases and 7,406 controls in colorectal cancer patients
with available stage, 1,008 cases and 4,900 controls in breast cancer patients with available stage and 1,520 cases and 7,473 controls in prostate cancer patients with available grade. cAdditionally adjusted for stage in
colorectal cancer patients and breast cancer patients and adjusted for grade in prostate cancer patient. dTests for trend from conditional logistic regression model based upon categories of DDDs (0, 1 to365, ≥365
DDDs coded as 0, 1, 2 respectively). ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CI, confidence interval; DDDs, daily defined doses; OR, odds ratio.
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ACEI and cancer progression, one [17] in prostate cancer
patients and two [15,16] in colorectal cancer patients.
An earlier ACEI study in 62 prostate cancer patients
after radical prostatectomy [17] observed a reduced rate
of biochemical recurrence in ACEI users compared with
non-users (3/32 versus 10/30). An earlier ACEI study in
55 stage 2 colorectal cancer patients [15] observed a re-
duction in the risk of distant metastasis with frequent
ACEI use prior to diagnosis (adjusted OR = 0.22) and a
more recent study in 262 stage 3 and 4 cancer patients
did not present an estimate for ACEI or ARB use separately
but did present a reduced risk of mortality in patients
simultaneously using beta-blockers and ACEIs or ARBs
(HR = 0.50 95% CI 0.29, 0.85).
Five independent epidemiological studies [13,14,18-20]
have previously investigated ACEI and cancer-specific
mortality in breast cancer patients but only two have
previously investigated ARB use separately. A recent large
Danish study [13] demonstrated a small but non-significant
increase in cancer recurrence with ACEI use but no as-
sociation with ARB use (HR = 1.2 95% CI 0.97, 1.4 and
HR = 1.1 95% CI 0.85, 1.3, respectively). Another recent
US study [14], from the same cohort as an earlier study
[34], observed no association between either ACEI use
Table 5 Sensitivity analyses for association between ACEIs and ARBS and cancer specific mortality in colorectal
cancer patients
Cancer specific
deaths number
Controls
number
OR (95% CI) P OR (95% CI) P
ACEI user versus
non user
ARB user versus
non user
Colorectal cancer
Main analysis: diagnosis to six months prior to deatha 1,093 5,231 0.76 (0.62, 0.93) 0.01 0.80 (0.59, 1.09) 0.16
Diagnosis to one year prior to deathb 869 4,152 0.83 (0.67, 1.03) 0.10 0.89 (0.64, 1.25) 0.51
Restricted to users of any antihypertensive medicationc prior
to cancer diagnosisd
427 1,934 0.83 (0.65, 1.07) 0.15 0.90 (0.63, 1.27) 0.54
Comparison group restricted to users of any antihypertensive
in exposure periodc
596 1,845 0.75 (0.61, 0.92) 0.01 0.80 (0.59, 1.10) 0.16
Additionally adjusting for other antihypertensivese 1,093 5,231 0.75 (0.61, 0.92) 0.01 0.80 (0.59, 1.09) 0.16
≥730 DDDs versus 0 DDDs (non-user) 1,093 5,231 0.73 (0.62, 1.00) 0.03 0.93 (0.64, 1.36) 0.72
Stage 1 and 2f 328 1,483 0.54 (0.38, 0.77) 0.001 0.80 (0.47, 1.37) 0.41
Stage 3 and 4f 740 3,185 0.86 (0.68, 1.10) 0.23 1.05 (0.72, 1.55) 0.79
Colon 649 3,134 0.84 (0.64, 1.09) 0.19 0.77 (0.52, 1.15) 0.21
Rectal 444 2,097 0.67 (0.49, 0.92) 0.01 0.91 (0.56, 1.50) 0.72
Males 638 3,078 0.80 (0.62, 1.03) 0.08 0.93 (0.62, 1.41) 0.74
Females 455 2,153 0.70 (0.49, 0.98) 0.04 0.64 (0.40, 1.03) 0.06
Pre-diagnostic useg 1,641 7,815 1.06 (0.89, 1.27) 0.51 0.86 (0.62, 1.18) 0.35
Time varying covariate analysish 1,109 2,559
≥1 DDDs versus 0 DDDs (non-user) 0.81 (0.69, 0.96) 0.01 0.86 (0.66, 1.12) 0.26
1 to365 DDDs versus 0 DDDs (non-user) 0.76 (0.59, 0.97) 0.03 0.64 (0.40, 1.03) 0.07
≥365 DDDs versus 0 DDDs (non-user) 0.85 (0.69, 1.03) 0.10 1.00 (0.73, 1.38) 0.99
≥1 DDDs versus 0 DDDs (non-user) in stage 1 and 2 patients 0.62 (0.46, 0.84) 0.002 0.65 (0.41, 1.05) 0.08
≥1 DDDs versus 0 DDDs (non-user) in stage 3 and 4 patients 0.91 (0.74, 1.10) 0.33 0.97 (0.70, 1.34) 0.83
aExcept where otherwise stated analysis investigates medications from diagnosis to six months prior to death/index date and models include surgery (within six
months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), low dose aspirin (during exposure period), statins (during exposure
period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic
pulmonary disease, peripheral vascular disease, renal disease, peptic ulcer disease and diabetes), smoking (pre-diagnosis, with missing included as a category) and
stage. bRestricted to individuals surviving more than 1.5 years. cAntihypertensive medications include beta-blockers, diuretics, vasodilator antihypertensive drugs,
centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, ACEIs, ARBs, renin inhibitors and calcium channel blockers. dRestricted to individuals
with >1 year of records prior to cancer diagnosis and pre-diagnostic use considered antihypertensive use in that year, excluding deaths in the year after cancer
diagnosis. eModels include all variables in a and additionally include calcium channel blockers, diuretics and beta-blockers. fStratified analyses were conducted
after re-matching controls to cases within strata, due to non-availability of matches overall numbers in subgroups may not be identical to numbers presented in
Table 1. gRestricted to individuals with >1 year of records prior to cancer diagnosis and pre-diagnostic use considered ACEI/ARB use in that year, not excluding
deaths in the year after cancer diagnosis. hReported estimates are adjusted hazard ratios and 95% CI, model contains age at diagnosis, year of diagnosis, gender,
site (colon or rectum), surgery (within six months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), statins (during exposure
period as a time varying covariate), comorbidities (pre-diagnosis including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic
pulmonary disease, peripheral vascular disease, renal disease, peptic ulcer disease and diabetes) and stage. ACEIs, angiotensin-converting enzyme inhibitors; ARBs,
angiotensin II receptor blockers; CI, confidence interval; DDDs, daily defined doses; OR, odds ratio.
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(HR = 1.07 95% CI 0.65, 1.77) or ARB use (HR = 0.41
95% CI 0.15, 1.13) and cancer-specific mortality. An earlier
smaller study [18], including 174 breast cancer-specific
deaths in 1,779 breast cancer patients, observed no as-
sociation with simultaneous ACEI and beta-blocker use
and when investigating ACEI users exclusively observed
a marked increase in cancer recurrence (HR = 1.56 95%
CI 1.02, 2.39) but little evidence of an increase in breast
cancer-specific mortality (HR = 1.27 95% CI 0.74, 2.19).
One study observed little evidence of association for
self-reported ACEI use (HR = 0.89 95% CI 0.60, 1.32)
[20]. Finally another study observed a marked reduction
in cancer recurrence in 168 stage 2 or 3 breast cancer
patients using ACEI or ARBs after diagnosis (HR = 0.57
95% CI 0.37, 0.89, P =0.01) [19], but this estimate may
have incurred some immortal time bias [29] as individuals
using ACEIs or ARBs after diagnosis were considered
users from diagnosis in the analysis so in the period from
diagnosis to medication use they could not have died.
Our study observed some protective effects of ACEIs,
particularly in early stage colorectal cancer patients and
prostate cancer patients, which, if real, would support the
theory that ACEIs have a role in cancer therapy [35,36].
Components of the renin-angiotensin system (RAS) are
expressed in various cancer sites [37] and may contribute
to processes important for cancer progression including
cell proliferation and apoptosis. In vitro and animal studies
have shown that both ACEIs and ARBs can suppress cell
proliferation and tumor/metastasis growth in various can-
cers including breast [38] and colorectal [39]. Angiogenesis
also appears to be an important process by which the RAS
system exerts pro-tumor effects and ACEIs and ARBs re-
duce the expression of vascular endothelial growth factor
(VEGF) and other angiogenic factors in both cell lines [38]
and animal models [40]. However, the protective effects ob-
served in colorectal and prostate cancer patients should be
interpreted cautiously because, as previously stated, the ef-
fects were weak, inconsistent and not a priori stated.
Table 6 Sensitivity analyses for association between ACEIs and ARBS and cancer specific mortality in prostate
cancer patients
Cancer specific
deaths number
Controls
number
OR (95% CI) P OR (95% CI) P
ACEI user versus
non user
ARB user versus
non user
Prostate cancer
Main analysis: diagnosis to six months prior to deatha 766 3,777 0.82 (0.67, 1.02) 0.07 0.82 (0.61, 1.11) 0.21
Diagnosis to one year prior to deathb 682 3,360 0.88 (0.70, 1.09) 0.24 0.89 (0.64, 1.23) 0.48
Adjusting for Gleason score along with all variables ina apart from grade 516 2,518 0.80 (0.62, 1.03) 0.09 0.89 (0.61, 1.31) 0.55
Restricted to users of any antihypertensive medicationc prior
to cancer diagnosisd
399 1,925 0.80 (0.62, 1.04) 0.09 0.89 (0.62, 1.26) 0.51
Comparison group restricted to users of any antihypertensive in
exposure periodc
584 2,753 0.78 (0.63, 0.96) 0.02 0.80 (0.59, 1.08) 0.15
Additionally adjusting for other antihypertensivese 766 3,777 0.74 (0.60, 0.92) 0.01 0.75 (0.55, 1.02) 0.07
Additionally adjusting for hormone therapy any time after diagnosisf 766 3,777 0.82 (0.66, 1.01) 0.06 0.84 (0.62, 1.14) 0.27
≥730 DDDs versus 0 DDDs (non-user) 766 3,777 0.91 (0.70, 1.18) 0.49 0.84 (0.59, 1.21) 0.36
Pre-diagnostic useg 821 4,041 0.98 (0.78, 1.23) 0.87 1.14 (0.75, 1.75) 0.53
Time varying covariate analysish 772 3,838
≥1 DDDs versus 0 DDDs (non-user) 0.90 (0.76, 1.07) 0.24 0.95 (0.73, 1.23) 0.70
1 to 365 DDDs versus 0 DDDs (non-user) 0.87 (0.70, 1.08) 0.21 0.88 (0.62, 1.26) 0.49
≥365 DDDs versus 0 DDDs (non-user) 0.94 (0.76, 1.18) 0.60 1.03 (0.72, 1.48) 0.86
aExcept where otherwise stated analysis investigates medications from diagnosis to six months prior to death/index date and models include surgery (within six
months of diagnosis), chemotherapy (within six months), radiotherapy (within six months), low dose aspirin (during exposure period), statins (during exposure
period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic
pulmonary disease, peripheral vascular disease, renal disease, peptic ulcer disease and diabetes), smoking (pre-diagnosis, with missing included as a category),
androgen therapy (within six months) and grade. bRestricted to individuals surviving more than 1.5 years. cAntihypertensive medications include beta-blockers,
diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, ACEIs, ARBs, renin inhibitors, and calcium
channel blockers. dRestricted to individuals with >1 year of records prior to cancer diagnosis and pre-diagnostic use considered antihypertensive use in that year,
excluding deaths in the year after cancer diagnosis.
eModels include all variables in aand additionally include calcium channel blockers, diuretics and beta-blockers. fModels include all variables in abut androgen
therapy was determined at any time after diagnosis in the exposure period. gRestricted to individuals with >1 year of records prior to cancer diagnosis and
pre-diagnostic use considered ACEI/ARB use in that year, not excluding deaths in the year after cancer diagnosis. hReported estimates are adjusted hazard ratios
and 95% CIs models contain year of diagnosis, age at diagnosis, surgery (within six months of diagnosis), chemotherapy (within six months), radiotherapy (within
six months), comorbidities (pre-diagnosis, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral
vascular disease, renal disease, peptic ulcer disease and diabetes), statin (as a time varying covariate) and grade. ACEIs, angiotensin-converting enzyme inhibitors;
ARBs, angiotensin II receptor blockers; CI, confidence interval; DDDs, daily defined doses; OR, odds ratio.
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Conclusions
In conclusion, concerns about the safety of ACEIs and
ARBs in cancer patients have been raised by trial data
showing increases in fatal cancers in ARB users [4] and
observational data showing increases in breast cancer
recurrence rates in ACEI users [18]. In contrast, our study
provides no evidence of increased risks of cancer-specific
mortality in users of ACEIs or ARBs with breast, prostate
or colorectal cancer and suggests that these medications
are safe in patients diagnosed with these common cancers.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study concept and design: CRC, CH, LJM. Acquisition of data: CRC, UCM, CH,
MMC, LJM. Analysis and interpretation of data: all authors. Drafting of the
manuscript: CRC. Critical revision of the manuscript for important intellectual
content: all authors. Statistical analysis: CRC, UCM, BMH. Obtained funding:
CRC, CH, LJM. All authors read and approved the final manuscript.
Acknowledgements
CRC was supported by a Health and Social Care Research and Development,
Public Health Agency, Northern Ireland, funded UK NIHR awarded Career
Development Fellowship. BMH and UCM were funded by Northern Ireland
Department of Education and Learning PhD studentships. Access to the
GPRD database was funded through the Medical Research Council’s license
agreement with the UK Medicines and Healthcare Products Regulatory
Agency. However, the interpretation and conclusions contained in this study
are those of the authors alone. None of the funders had any role in the design
and conduct of the study; collection, management, analysis, and interpretation
of the data; and preparation, review, or approval of the manuscript.
Author details
1Cancer Epidemiology and Health Services Research Group, Centre for Public
Health, Queen’s University Belfast, Belfast, Northern Ireland. 2School of
Pharmacy, Queen’s University Belfast, Belfast, Northern Ireland.
Received: 21 August 2013 Accepted: 14 January 2014
Published: 13 February 2014
References
1. Maddams J, Utley M, Moller H: Projections of cancer prevalence in the
United Kingdom, 2010–2040. Br J Cancer 2012, 107:1195–1202.
2. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L,
Scoppa S, Hachey M, Rowland JH: Cancer survivors in the United States:
prevalence across the survivorship trajectory and implications for care.
Cancer Epidemiol Biomarkers Prev 2013, 22:561–570.
3. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL: Prognostic
importance of comorbidity in a hospital-based cancer registry.
JAMA 2004, 291:2441–2447.
4. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL,
Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on
mortality and morbidity in patients with chronic heart failure: the
CHARM-Overall programme. Lancet 2003, 362:759–766.
5. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC: Angiotensin-receptor
blockade and risk of cancer: meta-analysis of randomised controlled trials.
Lancet Oncol 2010, 11:627–636.
6. Goldstein MR, Mascitelli L, Pezzetta F: Angiotensin-receptor blockade,
cancer, and concerns. Lancet Oncol 2010, 11:817–818.
7. Clere N, Corre I, Faure S, Guihot AL, Vessieres E, Chalopin M, Morel A,
Coqueret O, Hein L, Delneste Y, Paris F, Henrion D: Deficiency or blockade
of angiotensin II type 2 receptor delays tumorigenesis by inhibiting
malignant cell proliferation and angiogenesis. Int J Cancer 2010,
127:2279–2291.
8. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J,
Gupta AK, Sever PS, Gluud C, Messerli FH: Antihypertensive drugs and risk
of cancer: network meta-analyses and trial sequential analyses of
324,168 participants from randomised trials. Lancet Oncol 2011, 12:65–82.
9. Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L: Long term use of drugs
affecting the renin-angiotensin system and the risk of cancer: a population-
based case–control study. Br J Clin Pharmacol 2012, 74:180–188.
10. Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A: Use of angiotensin
receptor blockers and the risk of cancer. Circulation 2011, 123:1729–1736.
11. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S: Long-term
use of angiotensin receptor blockers and the risk of cancer. PLoS One
2012, 7:e50893.
12. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L: Angiotensin receptor
blockers and risk of cancer: cohort study among people receiving
antihypertensive drugs in UK General Practice Research Database.
BMJ 2012, 344:e2697.
13. Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, Cronin-Fenton
DP, Game JP, Christiansen PM, Lash TL, Ahern TP: Use of β-blockers,
angiotensin-converting enzyme inhibitors, angiotensin II receptor
blockers, and risk of breast cancer recurrence: a Danish nationwide
prospective cohort study. J Clin Oncol 2013, 31:2265–2272.
14. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK,
Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor M: Use of ACE
inhibitors and angiotensin receptor blockers and primary breast cancer
outcomes. J Cancer 2013, 4:549–556.
15. Heinzerling JH, Anthony T, Livingston EH, Huerta S: Predictors of distant
metastasis and mortality in patients with stage II colorectal cancer.
Am Surg 2007, 73:230–238.
16. Engineer DR, Burney BO, Hayes TG, Garcia JM: Exposure to ACEI/ARB and
beta-blockers is associated with improved survival and decreased tumor
progression and hospitalizations in patients with advanced colon cancer.
Transl Oncol 2013, 6:539–545.
17. Ronquist G, Frithz G, Wang YH, Lindeborg T: Captopril may reduce
biochemical (prostate-specific antigen) failure following radical
prostatectomy for clinically localized prostate cancer. Scand J Urol
Nephrol 2009, 43:32–36.
18. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW: Examining the influence
of beta blockers and ACE inhibitors on the risk for breast cancer
recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011,
129:549–556.
19. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W:
Reduced risk of breast cancer recurrence in patients using ACE
inhibitors, ARBs, and/or statins. Cancer Invest 2011, 29:585–593.
20. Holmes MD, Hankinson SE, Feskanich D, Chen WY: Beta blockers and
angiotensin-converting enzyme inhibitors’ purported benefit on breast
cancer survival may be explained by aspirin use. Breast Cancer Res Treat
2013, 139:507–513.
21. Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards
MA: Cancer recording and mortality in the General Practice Research
Database and linked cancer registries. Pharmacoepidemiol Drug Saf 2013,
22:168–175.
22. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ: Validation and
validity of diagnoses in the General Practice Research Database:
a systematic review. Br J Clin Pharmacol 2010, 69:4–14.
23. Clinical Practice Research Datalink: Ethical review for CPRD protocols.
[http://www.cprd.com/isac/otherinfo.asp]
24. British Medical Association and the Royal Pharmaceutical Society of Great
Britain: British National Formulary. [http://www.bnf.org/bnf/index.htm]
25. World Health Organisation: World Health Organisation Collaborating
Centre for Drug Statistics Methodology. [http://www.whocc.no/]
26. National Cancer Institute: Prostate cancer treatment. [http://www.cancer.
gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page2]
27. Khan NF, Perera R, Harper S, Rose PW: Adaptation and validation of the
Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010, 11:1.
28. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine
agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007,
356:29–38.
29. Levesque LE, Hanley JA, Kezouh A, Suissa S: Problem of immortal time bias
in cohort studies: example using statins for preventing progression of
diabetes. BMJ 2010, 340:b5087.
30. Etminan M: Pharmacoepidemiology II: the nested case–control study–a novel
approach in pharmacoepidemiologic research. Pharmacotherapy 2004,
24:1105–1109.
Cardwell et al. BMC Medicine 2014, 12:28 Page 14 of 15
http://www.biomedcentral.com/1741-7015/12/28
31. Essebag V, Platt RW, Abrahamowicz M, Pilote L: Comparison of nested
case–control and survival analysis methodologies for analysis of
time-dependent exposure. BMC Med Res Methodol 2005, 5:5.
32. Altman DG, Bland JM: Interaction revisited: the difference between two
estimates. BMJ 2003, 326:219.
33. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of
a competing risk. J Am Stat Assoc 1999, 94:496–509.
34. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT,
Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM:
Beta-blocker use is associated with improved relapse-free survival in
patients with triple-negative breast cancer. J Clin Oncol 2011, 29:2645–2652.
35. Ager EI, Neo J, Christophi C: The renin-angiotensin system and malignancy.
Carcinogenesis 2008, 29:1675–1684.
36. George AJ, Thomas WG, Hannan RD: The renin-angiotensin system and
cancer: old dog, new tricks. Nat Rev Cancer 2010, 10:745–759.
37. Deshayes F, Nahmias C: Angiotensin receptors: a new role in cancer?
Trends Endocrinol Metab 2005, 16:293–299.
38. Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X:
Angiotensin II type 1 receptor antagonists inhibit cell proliferation and
angiogenesis in breast cancer. Cancer Lett 2013, 328:318–324.
39. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C: Effect of ACE
inhibitors and angiotensin II receptor antagonists in a mouse model of
colorectal cancer liver metastases. J Gastroenterol Hepatol 2007, 22:577–584.
40. Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, Peng JJ: Effects of
angiotensin-converting enzyme inhibitors and angiotensin II type 1
receptor blockers on lymphangiogenesis of gastric cancer in a nude
mouse model. Chin Med J (Engl) 2008, 121:2167–2171.
doi:10.1186/1741-7015-12-28
Cite this article as: Cardwell et al.: Drugs affecting the renin-angiotensin
system and survival from cancer: a population based study of breast,
colorectal and prostate cancer patient cohorts. BMC Medicine 2014 12:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cardwell et al. BMC Medicine 2014, 12:28 Page 15 of 15
http://www.biomedcentral.com/1741-7015/12/28
